Rogerio C. Lilenbaum, MD, director of the Banner MD Anderson Cancer Center, discusses the ways physicians practicing in different care institutions order molecular panels for patients with nonsquamous non-small cell lung cancer (NSCLC). He believes almost every one of these patients should receive a molecular panel and a PD-L1 test. Additionally, while tissue-based molecular profiles have been used with success over the past few years, circulating tumor DNA (ctDNA) liquid biopsies can also be used and Dr. Lilenbaum suggests physicians can rely on the results for most molecular alterations.

Learn more by clicking here.